346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine

Attia argues that prostate cancer should not be a leading cause of death, and that with proper risk stratification, many biopsies can be avoided or targeted. He acknowledges that the algorithm is not simple, which is why population-level screening recommendations are cautious, but he personally uses this approach and believes it saves lives. He also notes that colon cancer is similarly preventable with colonoscopy, and that two of the top four cancer killers are largely avoidable.

Attia describes that his educated, affluent patients frequently send him clips about ivermectin curing cancer. Because he is busy, he responds glibly but always adds an offer to discuss. They usually decline, satisfied that he has dismissed it. He believes this approach works because it cuts through the noise while preserving the relationship, and it avoids the elitist tone that alienated many during COVID.

Attia argues that the COVID-19 response suffered because Dr. Fauci and others wore both hats, leading to confusion and distrust when recommendations changed. He believes the public would accept changing science if it were communicated honestly by a separate, impartial voice. He also notes that social media amplifies misinformation, but the solution is not to silence dissent but to fill the vacuum with honest dialogue. He points to the bone marrow transplant for breast cancer story as an example of how science can self-correct transparently.

Attia uses the ivermectin example to illustrate. He notes that the argument that pharma suppresses cures is illogical because they would patent a modified version and profit immensely. He emphasizes that the burden of proof is on the claimant to produce trial data. He also reflects on the medical community's mistake of mocking ivermectin as 'horse dewormer' rather than engaging with the evidence, which fueled the anti-establishment narrative.

Attia argues that a scientist must be an impartial observer who changes their mind with new data and has no attachment to past statements. An advocate, by contrast, must drive policy and sometimes settle for the best available action—'any port in a storm.' When one person wears both hats, the public cannot distinguish between evolving science and political expediency, and trust collapses. He is horrified that the narrative has not led to better preparedness, and fears that if a pandemic struck today, the response would be even worse due to eroded trust and the weaponization of health information. He acknowledges that social media amplifies misinformation, but insists the solution is not to silence dissent but to fill the vacuum with honest, evolving dialogue. He points to the bone marrow transplant for breast cancer debacle as an example of how science can self-correct when communicated transparently.

Attia explains that cancer is not one disease; each type (and subtype) has distinct biology, so a single agent cannot plausibly cure all. He notes that the argument that pharma suppresses cures is illogical because a company could patent a modified version and make enormous profits. He also reflects on the medical community's strategic error of dismissing ivermectin as 'horse dewormer' rather than engaging with the evidence. He personally reviewed the randomized controlled trials for ivermectin in COVID and found no signal except a flawed Brazilian study. He believes the elitist handling created a backlash where ivermectin became an 'anti-smartypants drug,' and that honest, data-driven communication would have been more effective.

Attia explains that PSA by itself is 'pretty bad,' but when you incorporate PSA density (PSA divided by prostate volume) and PSA velocity (rate of change over time), the predictive value for clinically significant cancer (Gleason 3+4 or higher) becomes quite high. He uses these metrics to stratify men before deciding on biopsy, and further refines with tests like PHI or 4K score and multiparametric MRI. He acknowledges this is not a simple turnkey solution, which is why guidelines are cautious, but he laments that too many men are dying unnecessarily. He also notes that colon cancer is similarly preventable with colonoscopy, and that two of the top four cancer killers should not be on the list.

Attia envisions AI handling labor-intensive tasks like study reports and toxicology reports, so that any remaining time in a trial is spent on human benefit, not administrative delay. He suggests that AI could enable safety monitoring in every patient receiving a drug, not just the trial population, vastly improving pharmacovigilance. He also sees AI reducing burnout among healthcare workers by decreasing documentation burdens. He draws an analogy to HIV viral load as a biomarker that accelerated drug development, and wishes for similar AI-enabled biomarkers for other cancers. He believes the protein folding work is just the beginning of AI's impact on preclinical drug discovery.

He believes that culture is not just top-down but something every employee should feel empowered to shape. He recounts a product development meeting at Genentech where someone suggested loosening the diagnostic criteria for Herceptin to increase sales. Both he and CEO Art Levinson spontaneously stood up and said, 'We never do that. We don't do that here.' He also describes how, at the Gates Foundation, he would subtly support presenters when Bill Gates grilled them—nodding, smiling, or gently stalling to give them space—to signal that he wanted them to succeed. These small acts, he argues, are the real fabric of culture.